People: Cree Inc (CREE.O)

CREE.O on Nasdaq

30.90USD
10:18am EDT
Change (% chg)

$0.34 (+1.11%)
Prev Close
$30.56
Open
$30.49
Day's High
$30.92
Day's Low
$30.47
Volume
190,317
Avg. Vol
1,895,297
52-wk High
$53.33
52-wk Low
$27.25

Search Stocks

Ingram, Robert 

Mr. Robert A. Ingram is Lead Independent Director of the company. Mr. Ingram joined the Board of Directors in December 2008 and has served as Lead Independent Director since October 2011. Since January 2007, he has been a General Partner in Hatteras Venture Partners, a venture capital firm that invests in early stage life science companies in the southeast United States, and he has also served as strategic advisor to the chief executive officer of GlaxoSmithKline plc, a publicly traded pharmaceutical research and development company. From 2003 through 2009, he served as Vice Chairman Pharmaceuticals, GlaxoSmithKline. He previously served as Chief Operating Officer and President of Pharmaceutical Operations of GlaxoSmithKline following the December 2000 merger of Glaxo Wellcome plc and SmithKline Beecham plc. Prior to the merger he served as Chief Executive Officer of Glaxo Wellcome plc and as Chairman, President and Chief Executive Officer of Glaxo Wellcome Inc. Mr. Ingram also serves on the Board of Directors of Edwards Lifesciences Corporation and Regeneron Pharmaceuticals, Inc., and serves as Lead Director of Valeant Pharmaceuticals International, Inc. He also served as Chairman of the Board of Directors of OSI Pharmaceuticals, Inc. from January 2003 until its sale in June 2010, and served on the Board of Directors of Elan Corporation, plc from December 2010 until its sale in December 2013 and as its Chairman from January 2011 until December 2013. He previously served as a director of Misys plc, Nortel Networks Corp., Wachovia Corp., Lowe’s Companies, Inc., Pharmaceutical Product Development, Inc. and Allergan, Inc. until 2005, 2006, 2008, May 2011, December 2011 and December 2012, respectively.

Basic Compensation

Total Annual Compensation, USD 62,500
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 77,281
Fiscal Year Total, USD 168,627

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Charles Swoboda

5,776,620

Michael McDevitt

2,134,320

Norbert Hiller

1,840,450

Robert Ingram

168,627

John Replogle

370,650

Alan Ruud

1,043,920
As Of  28 Jun 2014
Search Stocks